Han Yue

Prof. Han Yue


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Differentiation
Verified
Journal Article
Closed access
YZYuanyuan Zhang
Yuanyuan Zhang
PLPengju Lv
Pengju Lv
YLYalong Li
Yalong Li
YZYonghui Zhang
Yonghui Zhang
CCChaofei Cheng
Chaofei Cheng
HYHan Yue
Han Yue

22 December 2023 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
JWJianfa Wang
Jianfa Wang
GSGuoshao Sun
Guoshao Sun
FLFang Li
Fang Li
ZZZhi Zhu
Zhi Zhu
LSLei Sun
Lei Sun
HYHan Yue
Han Yue
Vitamin D deficiency is associated with various diseases such as obesity, digestive problems, osteoporosis, depression, and infections, and has therefore emerged as a topic of great interest in public healthcare. The quantitative assessment of 25-hydroxyvitamin D (25-OH VD) in human serum may accurately reflect the nutritional status of vitamin D in the human body, which is significant for the prevention and treatment of vitamin D-deficient patients. In this study, we developed an assay for quantitative detection of 25-OH VD based on the 25-OH VD monoclonal antibody (mAb), and identified the optimal process parameters. The following process settings were found to be suitable for the test strips: pH of 7.6, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) ratio of 1:2000, and the anti-25-OH VD mAb ratio was 1:8. The equilibration time of the immune dynamic assay was 15 min. Under optimal conditions, the quantum dot nanoparticle-based fluorescent immunochromatographic assay (QDs-FICA) exhibited dynamic linear detection of 25-OH VD in PBS, from 5 ng/mL to 100 ng/mL, and the strip quantitative curve could be represented by the following regression equation: y = −0.02088 logx)+1.444 (R2 = 0.9050). The IC50 of the QDs-FICA was 39.6 ± 1.33 ng/mL. The specificity of the QDs-FICA was evaluated by running several structurally related analogues, including 25-OH VD2, 25-OH VD3, 1,25-OH2VD3, 1,25-OH2VD2, VD2, and VD3. The coefficients of variation were all below 10%. The shelf life of the test strips in this study was about 160 days at room temperature. Briefly, this study is the first to perform QDs-FICA for the rapid visual and quantitative detection of 25-OH VD, with great potential significance for clinical diagnosis of vitamin D-associated diseases.

1 January 2023 in Current Stem Cell Research & Therapy
Verified
Journal Article
Closed access
PDF file
YZYuanyuan Zhang
Yuanyuan Zhang
PLPengju Lv
Pengju Lv
YLYalong Li
Yalong Li
YZYonghui Zhang
Yonghui Zhang
CCChaofei Cheng
Chaofei Cheng
HYHan Yue
Han Yue
Background: The prevalence of obesity, as well as obesity-induced chronic inflammatory diseases, is increasing worldwide. Chronic inflammation is related to the complex process of angiogenesis, and we found that adipose-derived stem cells from obese subjects (obADSCs) had proangiogenic features, including higher expression levels of interleukin-6 (IL-6), Notch ligands and receptors, and proangiogenic cytokines, than those from control subjects. We hypothesized that IL-6 and Notch signaling pathways are essential for regulating the proangiogenic characteristics of obADSCs. Objective: This study aimed to investigate whether the inflammatory cytokine interleukin 6 (IL-6) promotes the proangiogenic capacity of adipose stem cells in obese subjects via the IL-6 signaling pathway. Methods: We compared the phenotype analysis as well as cell doubling time, proliferation, migration, differentiation, and proangiogenic properties of ADSCs in vitro. Moreover, we used small interfering RNAs to inhibit the gene and protein expression of IL-6. Results: We found that ADSCs isolated from control individuals (chADSCs) and obADSCs had similar phenotypes and growth characteristics, and chADSCs had a stronger differentiation ability than obADSCs. However, obADSCs were more potent in promoting EA.hy926 cell migration and tube formation than chADSCs in vitro. We confirmed that IL-6 siRNA significantly reduced the transcriptional level of IL-6 in obADSCs, thereby reducing the expression of vascular endothelial growth factor (VEGF)- A, VEGF receptor 2, transforming growth factor β, and Notch ligands and receptors in obADSCs. Conclusion: The finding suggests that inflammatory cytokine interleukin-6 (IL-6) promotes the proangiogenic ability of obADSCs via the IL-6 signaling pathway.

7 September 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Closed access
PDF file
LALemei An
Lemei An
TCTianshu Chu
Tianshu Chu
LWLiujun Wang
Liujun Wang
SASongtao An
Songtao An
YLYalong Li
Yalong Li
HYHan Yue
Han Yue
A single injection of low‑dose human umbilical cord‑derived mesenchymal stem cells (UC‑MSCs) has been previously demonstrated to relieve synovitis and bone erosion in animal models of arthritis, but whether frequent injections of high‑dose UC‑MSCs relieve arthritis and inhibit loss of muscle mass has remained elusive. In the present study, DBA/1 mice were randomly divided into three groups: Normal (wild‑type mice; n=11), collagen‑induced arthritis (CIA; n=12) and CIA treated with UC‑MSCs (n=11; 5x106 UC‑MSCs per week for 3 weeks). Arthritis and skeletal muscle cachexia were evaluated until the end of the experiment on day 84. It was indicated that both the CIA and UC‑MSC groups had lower body weights compared with the normal mice. Clinical arthritis scores, hind ankle diameters, synovitis and bone erosion progressively increased and were similar between the CIA and UC‑MSC groups. Although there was no difference in food intake among the three groups, the normalized food intake of normal group was significantly higher than CIA group and UC‑MSC group from day 42 onwards; there was no significance on day 77 but this could be neglected. Furthermore, gastrocnemius muscle weight in the UC‑MSC group was significantly reduced compared with that in the CIA and normal groups. The UC‑MSC group had higher levels of proinflammatory cytokines, such as TNF‑α, IL‑6 and IL‑1β than those in the CIA group. However, the other cytokines assessed and the fibrosis indices in the CIA and UC‑MSC groups were not different from those in the control group and there was no inflammatory cell infiltration. Thus, frequent injections of high‑dose UC‑MSCs slightly aggravated synovitis and muscle cachexia in the murine CIA model and should therefore be avoided in the treatment of arthritis.

21 August 2025 in Clinical and Translational Medicine
Verified
Journal Article
Open access
XLXiaoying Luo
Xiaoying Luo
JDJieping Deng
Jieping Deng
XJXiaoke Jiang
Xiaoke Jiang
JMJun Mi
Jun Mi
YBYangqiu Bai
Yangqiu Bai
BZBingyong Zhang
Bingyong Zhang
Background: Ulcerative colitis (UC) is an agnogenic chronic intestinal inflammatory disease. Umbilical cord‐derived mesenchymal stem cell (UMSC) is a potential therapeutic approach against UC; however, the mechanisms underlying their efficacy for UC remain unclear. Methods: We performed a single‐arm clinical trial with 6 months follow‐up to assess the efficacy of UMSC in patients with moderate to severe left‐sided UC. The 26 enrolled patients were administered two UMSC doses intravenously. Pre‐ and post‐therapy colon biopsy specimens were analysed by single‐cell RNA sequencing (scRNA‐seq). Dextran sulphate sodium (DSS)‐induced colitis mouse models with or without UMSC injection were used to delineate colon inflammation and T cell function. Results: In the clinical trial, the clinical response/remission rates were 80.8/46.2% and 75.0/37.5% after 2 and 6 months of therapy, respectively. Endoscopic and histological examinations showed improvement of colonic mucosa after UMSC therapy in responders. scRNA‐seq data showed that UMSC therapy may suppress pro‐inflammatory features of T lymphocytes and alleviate inflammatory responses by inhibiting the interaction of T cells with B and myeloid cells. In the murine experiment, UMSCs suppressed DUOX2‐mediated oxidative stress to attenuate DSS‐induced colitis by regulating T cell‐mediated immunity. Conclusion: UMSC therapy primarily modulates T cell‐mediated immunity to achieve gut mucosal immune reconstitution and maintain mucosal barrier integrity, thereby achieving effective UC recovery. Highlights: UMSCs effectively induce clinical remission in patients with active UC via T cell‐mediated immune reconstitution. scRNA‐seq analyses further revealed that UMSC therapy suppressed pro‐inflammatory features of T cells and alleviated inflammatory responses by inhibiting the interaction of T cells with B and myeloid cells UMSCs suppressed DUOX2‐mediated oxidative stress to attenuate DSS‐induced colitis by regulating T cell‐mediated immunity.

6 October 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YJYu Jiang
Yu Jiang
RLRuibo Li
Ruibo Li
YBYueyao Ban
Yueyao Ban
WZWenjin Zhang
Wenjin Zhang
NKNing Kong
Ning Kong
HZHui Zhang
Hui Zhang
Hypoxic-ischemic encephalopathy (HIE) is a diffuse brain tissue injury caused by acute ischemia and hypoxia, and it is most commonly found in newborn infants but can also occur in adults. Mesenchymal stem cell (MSC) therapies have showed improved outcomes for treating HIE-induced neuronal defects. However, many key issues associated with poor cell viability and tolerance of grafted MSCs after HIE remain to be resolved. Genetic engineering could endow MSCs with more robust regenerative capacities. Our research, along with that of other scientists, has found that the expression of intracellular erythropoietin (EPO) in human umbilical cord MSCs (hUC-MSCs) increases proportionally with the duration of hypoxia exposure. Furthermore, we observed that EPO, when introduced into the EPO gene-modified hUC-MSCs, can be secreted into the extracellular space. However, the underlying mechanisms that support the neuroprotective effects of EPO-MSCs remain unclear. EPO-MSCs, hUC-MSCs, and NC-MSCs were identified by flow cytometry, osteogenic, and adipogenic differentiation assays. The oxygen-glucose deprivation (OGD)-induced SH-SY5Y cell-line was established, and five groups were set up: control, 24-h ischemia-hypoxia, co-cultured with hUC-MSCs, NC-MSCs, and EPO-MSCs after hypoxia. LEGENDplex™ multi-factor flow cytometry was used to detect the secretion of inflammatory factors in cell supernatants and cerebrospinal fluid. Chromosome-targeted excision and tagging (CUT&Tag) sequencing was applied to detect genomic H3K4me2 modifications, and conjoint analysis with transcriptome sequencing (RNA-seq) was performed. Lentiviral vector infection was used to construct SH-SY5Y cells with stable knockdown of RE1-silencing transcription factor (REST), and flow cytometry was used to detect alterations in apoptosis. Finally, the molecular mechanism underlying the neuroprotective and anti-apoptotic effects of EPO-MSCs was investigated using RNA sequencing, qRT-PCR, and western blot assays. Our results suggest that EPO-MSCs are genetically engineered to secrete significantly more EPO. EPO-MSCs treatment has anti-apoptotic properties and offers neuronal protection during ischemic-hypoxic injury. Furthermore, RNA-seq results suggest that multiple inflammation-related genes were down-regulated after EPO-MSCs treatment. Application of RNA-seq and CUT&Tag combined analysis found that the expressions of REST were significantly up-regulated. Lentiviral vector infection to construct REST knockdown SH-SY5Y failed to rescue apoptosis after hypoxia and co-culture with EPO-MSCs, and SETD2-mediated H3K36me3 protein level expression was reduced. EPO-MSCs may promote neuronal survival by affecting H3K4me2 and thus activating the expression of REST and TET3. EPO-MSCs also upregulated the modification level of SETD2-mediated H3K36me3 and regulated the expression of inflammation-related genes such as PLCG2, as well as apoptosis genes BCL2A1. To investigate the neuroprotective effects of EPO-modified hUC-MSCs and the underlying epigenetic regulatory mechanisms, this study aims to provide a theoretical foundation for the potential application of EPO gene-modified hUC-MSCs in the treatment of HIE.